

Edge Therapeutics, Inc.  
Form 8-K  
February 19, 2016

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

---

FORM 8-K

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 19, 2016

---

Edge Therapeutics, Inc.  
(Exact name of Registrant as specified in its charter)

---

Delaware 001-37568 26-4231384  
(State or Other Jurisdiction (Commission (I.R.S. Employer  
of Incorporation or Organization) File Number) Identification No.)

200 Connell Drive, Suite 1600  
Berkeley Heights, NJ 07922  
(800) 208-3343

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

Not Applicable  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Edgar Filing: Edge Therapeutics, Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

Item 7.01. Regulation FD Disclosure

On February 19, 2016, Dr. Daniel Hänggi, the worldwide principal investigator for Edge Therapeutics Inc. (the “Company”) in the Company’s Phase 1/2 NEWTON Trial for its lead product candidate, EG-1962, presented at the International Stroke Conference in Los Angeles, California. The presentation materials used by Dr. Hänggi are furnished as Exhibit 99.1 hereto. These materials may also be used at one or more subsequent conferences and are available on the Company’s website at [www.edgetherapeutics.com](http://www.edgetherapeutics.com).

In addition, on February 19, 2016, the Company released a press release regarding the International Stroke Conference. A copy of the Company’s press release regarding the conference is furnished as Exhibit 99.2 hereto.

In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the Exhibits hereto is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The information in this Item 7.01, as well as the Exhibits hereto, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K, which is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits

Exhibit Number	Description
99.1	International Stroke Conference Scientific Presentation Materials dated as of February 19, 2016
99.2	Press Release dated February 19, 2016

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 19, 2016 Edge Therapeutics, Inc.

By: /s/ Andrew J. Einhorn  
Name: Andrew J. Einhorn  
Title: Chief Financial Officer

---

EXHIBIT INDEX

Exhibit Number	Description
-------------------	-------------

99.1	International Stroke Conference Scientific Presentation Materials dated as of February 19, 2016
------	---

99.2	Press Release dated February 19, 2016
------	---------------------------------------

---